Replies to post #2080 on GTC Biotherapeutics (fka GTCB)

[waynebio]

Dew,

I find the discussion of the sharing arrangement with LFB to be a bit vague in the proxy and hope you can help. It talks about developing jointly to share profits then talks about exclusive rights in Europe for LFB
========================================================
Reading the proxy please clarify what it means that LFB gets exclusive European commercial rights. What benifit from Europe sales of rhFVIIa does GTCB expect?

What is GTCB expected to spend to develop rhFVIIa in Europe as part of this agreement, perhaps the production system contribution will not be very expensive?

What help can we expect from LFB when GTCB goes for US FDA approval...sharing of clinical/regulatory info from Europe?

[flatlander_60048]

I did not mean to convey the impression that LFB would not pull their weight in the relationship. Rather, I would liked to have seen a deal structured with some milestone payments to help with GTC's future cash burn. I guess that would reflect a licensing agreement rather than a 50-50 partnership. Since GTC has not yet tested any product in the area, a partnership is more appropriate.

Are you aware of LFB entering into similar collaborative partnerships? What is the track record for LFB in collaborative agreements?

GTC will tie up some resources and will probably increase the cash burn, but the market for FVIIa should be lucrative for a low cost producer bringing a product to market. The question is to what extent will ATryn and revenue from other licensing agreements be able to sustain GTC in the future. What is your best guess as to when financing will be come an issue again (18 months or longer?).

Thanks for your thoughts. This is the type of vote that only time can provide answers to. I'm not terribly swayed by the BOD recommendation since collectively they hold relatively few shares and most of their percentage ownership is in the form of options. But I do believe management sees enough upside to warrant the risks inherent in the partnership.

I realize each of us need to reach our own conclusions and vote our shares accordingly.

Thanks for your thoughts

FL

[Spice is nice]

"However, I can point to an aspect of the LFB deal that you may be overlooking: that FVIIa is one the most promising plasma proteins"

It is also one of the most difficult to succeed at.

Does anyone not married to this stock care to predict the chances of GTC' success in this arena? at a cost of 20% of the entire company?